TGFB1 and glomerulosclerosis: In their study, use of MCC950 in STZ-induced diabetic mice identified detrimental effects linked to NLRP3 inhibition, which resulted in upregulation of the expression of markers of inflammation (IL1β, IL18 and MCP1) and fibrosis (collagen I, collagen IV and transforming growth factor beta 1 (TGFβ1)) in addition to increased immune cell infiltration, mesangial expansion, and glomerulosclerosis (Østergaard et al., 2022).